GoodRx Holdings (GDRX) Gains from Sales and Divestitures (2020 - 2022)

GoodRx Holdings has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $2.7 million for Q4 2022.

• Gains from Sales and Divestitures for Q4 2022 came in at $2.7 million, up 466.81% year-over-year; the trailing twelve-month figure through Dec 2022 was $2.7 million (up 466.81% YoY), and the FY2022 annual result was $2.7 million, up 466.81% from the prior year.
• Gains from Sales and Divestitures came in at $2.7 million for Q4 2022 at GoodRx Holdings, up from $743000.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $16.4 million in Q4 2020 to a low of $118000.0 in Q2 2021.
• The 3-year median for Gains from Sales and Divestitures is $513000.0 (2021), against an average of $2.3 million.
• Across the five-year window, Gains from Sales and Divestitures tumbled 97.14% in 2021 and jumped 466.81% in 2022, its largest moves.
• GoodRx Holdings' Gains from Sales and Divestitures stood at $16.4 million in 2020, then sank by 97.14% to $470000.0 in 2021, then surged by 466.81% to $2.7 million in 2022.
• The last three Gains from Sales and Divestitures figures came in at $2.7 million (Q4 2022), $743000.0 (Q3 2022), and $546000.0 (Q2 2022), per Business Quant data.